Which organizations have issued guidelines on preexposure prophylaxis (PrEP) against HIV infection?

Updated: Oct 08, 2019
  • Author: Alejandro Delgado, MD; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print


The CDC first issued guidelines for preexposure prophylaxis (PrEP) in May 2014. These were updated in 2017 to incorporate the growing body of data. [25] Daily oral PrEP with the fixed-dose combination of tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg (Truvada) has been shown to be safe and effective in reducing the risk of sexual HIV acquisition in adults and adolescents weighing at least 35 kg. Daily emtricitabine/tenofovir is one prevention option that is part of the general guidelines for HIV prevention.

In October 2019, the FDA approved the fixed-dose combination of tenofovir alafenamide (TAF) 25 mg plus FTC 200 mg (Descovy) for at-risk adults and adolescents for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. [9]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!